TC BIOPHARM (HOLDINGS) PLC SPON ADS EACH REP 4000 SHS (POST SPLIT)(TCBPY.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
TC BIOPHARM (HOLDINGS) PLC SPON ADS EACH REP 4000 SHS (POST SPLIT)
TCBPY.US
1.944 T
TCBPY.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TC BioPharm Limited Enters Administration; Joint Administrators Seek Sale of Subsidiary's Assets

    TC BioPharm Limited has entered administration, with joint administrators Michael Magnay and Rob Croxen appointed to seek a sale of its business and assets, including intellectual property and R&D assets. TC BioPharm (Holdings) plc remains operational and is not affected by the administration process.

    Reuters·
    US
    TCBP
    0.00%
    Reuters·
    US
    TCBP
    0.00%

    TC BioPharm reports complete response in MRD patient after 2nd dose of TCB008. First in Cohort B.Announced in Edinburgh.

    A patient in Cohort B has successfully achieved complete remission after receiving their second dose of TCB008 in Edinburgh, Scotland. This significant development was reported by TC BioPharm (Holdings) PLC, a company listed on NASDAQ under the ticker symbol TCBP. They specialize in developing cutting-edge gamma delta T cell therapies to combat cancer. This breakthrough marks a critical milestone in the field of cancer treatment and highlights the promising potential of this innovative therapy.

    Unusual Whales·
    US
    TCBPY
    -40.83%
    US
    TCBP
    0.00%
    Unusual Whales·
    US
    TCBPY
    -40.83%
    US
    TCBP
    0.00%

    08:30 ET TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

    TC BioPharm (Holdings) PLC announced that the first patient in Cohort B, who had detectable Minimal Residual Disease (MRD), achieved complete molecular remission after receiving the second dose of their lead drug candidate TCB008. The patient received a total of approximately 500 million gamma delta T-cells over two weeks and remains in remission two months post-treatment. This milestone highlights TCB008's potential as a foundational therapy for blood cancer patients, aiming to improve long-term outcomes and prevent disease progression.

    prnewswire·
    US
    TCBP
    0.00%
    US
    TCBPY
    -40.83%
    prnewswire·
    US
    TCBP
    0.00%
    US
    TCBPY
    -40.83%

    Why TC Biopharm (TCBP) Stock Is Down Over 60% Today

    TC Biopharm (TCBP) shares plummeted by 64% after the company announced its transition from Nasdaq to OTC markets due to a delisting notice for failing to meet the $1.00 minimum bid price requirement. The clinical-stage biotech firm is appealing Nasdaq's decision. TCBP's stock has seen a 52-week high of $523.20 and a low of $0.54.

    Benzinga·
    US
    TCBP
    0.00%
    US
    TCBPY
    -40.83%
    Benzinga·
    US
    TCBP
    0.00%
    US
    TCBPY
    -40.83%

    TCBP Announces Transition from Nasdaq to OTC Markets | TCBP Stock News

    TC BioPharm (Holdings) PLC announced its transition from Nasdaq to OTC Markets after receiving notice of delisting due to non-compliance with minimum bid price requirements. Effective March 24, 2025, trading on Nasdaq will be suspended, and the company's American Depositary Shares will begin trading on OTC Markets. Despite the transition, TC BioPharm remains committed to its research and clinical trials in gamma-delta T cell therapies for cancer.

    StockTitan·
    US
    TCBP
    0.00%
    US
    TCBPY
    -40.83%
    StockTitan·
    US
    TCBP
    0.00%
    US
    TCBPY
    -40.83%
    © 2026 Longbridge｜Disclaimer